Browsing Tag
GSK plc
15 posts
Could Biogen and UCB finally crack one of biotech’s toughest lupus markets?
Biogen and UCB have a lupus win, but one more Phase 3 test decides the story. See why dapirolizumab pegol matters now.
GSK’s bepirovirsen wins FDA priority review as chronic hepatitis B strategy enters decisive phase
GSK has FDA momentum in hepatitis B. The harder question is whether bepirovirsen can turn functional cure into a real market shift.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
GSK wins China approval for Trelegy Ellipta in asthma, expanding respiratory market reach
Trelegy Ellipta is now approved for asthma in China, giving GSK dual coverage in COPD and asthma. Find out what this means for respiratory market dynamics.
GSK reshapes ViiV Healthcare ownership as Shionogi replaces Pfizer with $2.1bn investment
Pfizer exits ViiV Healthcare as Shionogi boosts its stake to 21.7%. Find out how GSK is reshaping HIV strategy with a streamlined ownership structure.
GSK to acquire RAPT Therapeutics in strategic push into long-acting food allergy biologics
GSK to acquire RAPT Therapeutics for $2.2B, targeting food allergy breakthroughs with ozureprubart. Find out how this changes its immunology strategy.
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix